The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
High-Dose Chemotherapy and Stem-Cell Rescue for Metastatic Germ-Cell Tumors
Open accessAbstract
BACKGROUND: Metastatic testicular tumors that have not been successfully treated by means of initial chemotherapy are potentially curable with salvage chemotherapy. METHODS: We conducted a retrospective review of 184 consecutive patients with metastatic testicular cancer that had progressed after they received cisplatin-containing combination chemotherapy. We gave 173 patients two consecutive courses of high-dose chemotherapy consisting of 700 mg of carboplatin per square meter of body-surface area and 750 mg of etoposide per square meter, each for 3 consecutive days, and each followed by an infusion of autologous peripheral-blood hematopoietic stem cells; the other 11 patients received a single course of this treatment. In 110 patients, cytoreduction with one or two courses of vinblastine plus ifosfamide plus cisplatin preceded the high-dose chemotherapy. RESULTS: Of the 184 patients, 116 had complete remission of disease without relapse during a median follow-up of 48 months (range, 14 to 118). Of the 135 patients who received the treatment as second-line therapy, 94 were disease-free during follow-up; 22 of 49 patients who received treatment as third-line or later therapy were disease-free. Of 40 patients with cancer that was refractory to standard-dose platinum, 18 were disease-free. A total of 98 of 144 patients who had platinum-sensitive disease were disease-free, and 26 of 35 patients with seminoma and 90 of 149 patients with nonseminomatous germ-cell tumors were disease-free. Among the 184 patients, there were three drug-related deaths during therapy. Acute leukemia developed in three additional patients after therapy. CONCLUSIONS: Testicular tumors are potentially curable by means of high-dose chemotherapy plus hematopoietic stem-cell rescue, even when this regimen is used as third-line or later therapy or in patients with platinum-refractory disease.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1992) · Springer Series in Statistics · doi:10.1007/978-1-4612-4380-9_25 · Cited by 45,181
An Introduction to the Bootstrap
Efron, B., & Tibshirani, R. J. (1994) · doi:10.1201/9780429246593 · Cited by 40,500
Nonparametric Estimation from Incomplete Observations
Kaplan, E. L., & Meier, P. (1958) · Journal of the American Statistical Association · doi:10.1080/01621459.1958.10501452 · Cited by 39,158
(1997) · Journal of Clinical Oncology · doi:10.1200/jco.1997.15.2.594 · Cited by 1,929
Williams, S. D., Birch, R., Einhorn, L. H., Irwin, L., Greco, F. A., & Loehrer, P. J. (1987) · New England Journal of Medicine · doi:10.1056/nejm198706043162302 · Cited by 1,170
Self-citationMead, G. M., Stenning, S. P., Cook, P. A., Fosså, S. D., Horwich, A., Kaye, S. B., Oliver, R. T. D., deMulder, P., deWit, R., Stoter, G., et al. (1997) · University of Groningen research database (University of Groningen / Centre for Information Technology) · Cited by 1,033
Bosl, G. J., & Motzer, R. J. (1997) · New England Journal of Medicine · doi:10.1056/nejm199707243370406 · Cited by 891
Development and Validation of a Risk Score for Predicting Death in Chagas' Heart Disease
Rassi, A., Rassi, A., Little, W. C., Xavier, S. S., Rassi, S. G., Rassi, A. G., Rassi, G. G., Hasslocher-Moreno, A., Sousa, A. S., & Scanavacca, M. I. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa053241 · Cited by 646
Treatment of testicular cancer: a new and improved model.
Einhorn, L. H. (1990) · Journal of Clinical Oncology · doi:10.1200/jco.1990.8.11.1777 · Cited by 504
Self-citationKondagunta, G. V., Bacik, J., Donadio, A., Bajorin, D., Marion, S., Sheinfeld, J., Bosl, G. J., & Motzer, R. J. (2005) · Journal of Clinical Oncology · doi:10.1200/jco.2005.19.638 · Cited by 418
Cited by
Breast Cancer, Version 4.2017, NCCN Clinical Practice Guidelines in Oncology
Gradishar, W. J., Anderson, B. O., Balassanian, R., Blair, S. L., Burstein, H. J., Cyr, A., Elias, A. D., Farrar, W. B., Forero, A., Giordano, S. H., et al. (2018) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2018.0012 · Cited by 1,609
Testicular Cancer, Version 2.2020, NCCN Clinical Practice Guidelines in Oncology
Gilligan, T., Lin, D. W., Aggarwal, R., Chism, D., Cost, N., Derweesh, I. H., Emamekhoo, H., Feldman, D. R., Geynisman, D. M., Hancock, S. L., et al. (2019) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2019.0058 · Cited by 450
Rajpert-De Meyts, E., McGlynn, K. A., Okamoto, K., Jewett, M. A. S., & Bokemeyer, C. (2016) · The Lancet · doi:10.1016/s0140-6736(15)00991-5 · Cited by 398
Ljungman, P., Bregni, M., Brune, M., Cornelissen, J., Witte, T. D., Dini, G., Einsele, H., Gaspar, H. B., Gratwohl, A., Passweg, J., et al. (2010) · Bone Marrow Transplantation · doi:10.1038/bmt.2009.141 · Cited by 388
Medical Treatment of Advanced Testicular Cancer
Feldman, D. R. (2008) · JAMA · doi:10.1001/jama.299.6.672 · Cited by 370
Testicular Cancer — Discoveries and Updates
Hanna, N. H., & Einhorn, L. H. (2014) · New England Journal of Medicine · doi:10.1056/nejmra1407550 · Cited by 345
Self-citationSureda, A., Bader, P., Cesaro, S., Dreger, P., Duarte, R. F., Dufour, C., Falkenburg, J. H. F., Farge-Bancel, D., Gennery, A., Kröger, N., et al. (2015) · Bone Marrow Transplantation · doi:10.1038/bmt.2015.6 · Cited by 337
for the European Society for Blood and Marrow Transplantation (EBMT), Duarte, R. F., Labopin, M., Bader, P., Basak, G. W., Bonini, C., Chabannon, C., Corbacioglu, S., Dreger, P., Dufour, C., et al. (2019) · Bone Marrow Transplantation · doi:10.1038/s41409-019-0516-2 · Cited by 337
ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up
Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., Clarke, N., Cohn-Cedermark, G., Daugaard, G., Dieckmann, K.-P., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy217 · Cited by 326
The International Prognostic Factors Study Group (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.26.8128 · Cited by 322
Beyer, J., Albers, P., Altena, R., Aparicio, J., Bokemeyer, C., Busch, J., Cathomas, R., Cavallin-Stahl, E., Clarke, N. W., Claßen, J., et al. (2013) · Annals of Oncology · doi:10.1093/annonc/mds579 · Cited by 320
Ovarian Cancer, Version 1.2016, NCCN Clinical Practice Guidelines in Oncology
Morgan, R. J., Armstrong, D. K., Alvarez, R. D., Bakkum-Gamez, J. N., Behbakht, K., Chen, L.-M., Copeland, L., Crispens, M. A., DeRosa, M., Dorigo, O., et al. (2016) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2016.0122 · Cited by 311
Lorch, A., Bascoul-Mollevi, C., Kramar, A., Einhorn, L., Necchi, A., Massard, C., De Giorgi, U., Fléchon, A., Margolin, K., Lotz, J.-P., et al. (2011) · Journal of Clinical Oncology · doi:10.1200/jco.2010.32.6678 · Cited by 273
Self-citationAdra, N., Einhorn, L. H., Althouse, S. K., Ammakkanavar, N. R., Musapatika, D., Albany, C., Vaughn, D., & Hanna, N. H. (2018) · Annals of Oncology · doi:10.1093/annonc/mdx680 · Cited by 196
Self-citationSystemic immune-inflammation index in germ-cell tumours
Chovanec, M., Cierna, Z., Miskovska, V., Machalekova, K., Kalavska, K., Rejlekova, K., Svetlovska, D., Macak, D., Spanik, S., Kajo, K., et al. (2018) · British Journal of Cancer · doi:10.1038/bjc.2017.460 · Cited by 90
Phase II Study of Avelumab in Multiple Relapsed/Refractory Germ Cell Cancer
Mego, M., Svetlovska, D., Chovanec, M., Rečkova, M., Rejlekova, K., Obertova, J., Palacka, P., Sycova-Mila, Z., De Giorgi, U., & Mardiak, J. (2019) · Investigational New Drugs · doi:10.1007/s10637-019-00805-4 · Cited by 81
Zschäbitz, S., Lasitschka, F., Hadaschik, B., Hofheinz, R.-D., Jentsch-Ullrich, K., Grüner, M., Jäger, D., & Grüllich, C. (2017) · European Journal of Cancer · doi:10.1016/j.ejca.2017.01.033 · Cited by 75
Albany, C., Einhorn, L., Garbo, L., Boyd, T., Josephson, N., & Feldman, D. R. (2018) · The Oncologist · doi:10.1634/theoncologist.2017-0544 · Cited by 51
Self-citationChi, E. A., & Schweizer, M. T. (2017) · Clinical Genitourinary Cancer · doi:10.1016/j.clgc.2017.04.005 · Cited by 37
Sadigh, S., Farahani, S. J., Shah, A., Vaughn, D., & Lal, P. (2020) · American Journal of Clinical Pathology · doi:10.1093/ajcp/aqz184 · Cited by 26
Loh, K. P., & Fung, C. (2017) · Rare Tumors · doi:10.4081/rt.2017.6867 · Cited by 23
Phase II Trial of Brentuximab Vedotin in Relapsed/Refractory Germ Cell Tumors
Ashkar, R., Feldman, D. R., Adra, N., Zaid, M. A., Funt, S. A., Althouse, S. K., Perkins, S. M., Snow, C. I., Lazzara, K. M., Sego, L. M., et al. (2021) · Investigational New Drugs · doi:10.1007/s10637-021-01134-1 · Cited by 16
Self-citation
Metadata
- Authors
- Einhorn, L. H., Williams, S. D., Chamness, A., Brames, M. J., Perkins, S. M., & Abonour, R.
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2007-07-26
- Volume
- 357
- Issue
- 4
- Pages
- 340-348
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2042770658
- Cited by
- 496
- References
- 23
- FWCI
- 24.77
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.